A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
Recruiting now · Phase 2
Conditions studied: Schizophrenia
In brief
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
Key facts
- Study ID
- NCT07459647
- Run by
- MapLight Therapeutics
- People needed
- 500
- Starts
- 2026-03-31
- Expected to finish
- 2030-02-01
- Last updated by the study team
- 2026-04-22
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Clinical Site — Lemon Grove, California, United States (enrolling)
- Clinical Site — Miami Lakes, Florida, United States (enrolling)
- Clinical Site — Chicago, Illinois, United States (enrolling)
- Clinical Site — Staten Island, New York, United States (enrolling)
- Clinical Site — DeSoto, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.